CA
RAPT

CoreCap Advisors’s RAPT Therapeutics RAPT Stock Holding History

CoreCap Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28
Closed -$276 – 3153
2025
Q1 		$276 Buy
+28
New +$275 ﹤0.01% 2833
2024
Q4 		– Sell
-79
Closed -$1.26K – 2956
2024
Q3 		$1.26K Buy
+79
New +$1.6K ﹤0.01% 2238

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

CoreCap Advisors's RAPT Position: Q2 2025 in Review

CoreCap Advisors sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 28 shares — an estimated $276 sold.

CoreCap Advisors first reported a position in RAPT in Q3 2024 and held it in 2 quarters. The position peaked at $1.26K in Q3 2024. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • CoreCap Advisors reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 28 RAPT Therapeutics shares in Q2 2025, an estimated $276.
  • CoreCap Advisors first reported a position in RAPT Therapeutics in Q3 2024 and held it in 2 quarters.
  • CoreCap Advisors's RAPT Therapeutics position peaked at $1.26K in Q3 2024.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.